Table 2.
miRNAs | Targets and Pathways | Sense of Dyregulation in TNBC | Role of miRNA in TNBC | References |
---|---|---|---|---|
miR-31 | Downregulated | Anti-tumoural | [46] | |
DLK1-DIO3 region (miRs 300, 382, 494, 495, 539, 543, and 544) | TWIST1, BMI1, ZEB1/2, and miR-200 family | Downregulated | Anti-tumoural | [61] |
miR200a | ZEB1, ZEB2 and SUZ12 E-cadherin pathway EPH receptor A2 (EPHA2) EPHA2 pathway |
Downregulated | Anti-tumoural | [62] |
miR200b | PKCα/Rac1 | Downregulated | Anti-tumoural | [63] |
miR-200c | ZEB1 | Downregulated | Anti-tumoural | [64] |
miR-30a | Inhibition of ROR1 | Downregulated | Anti-tumoural | [65] |
miR-146a | Inhibition of RhoA | Downregulated | Anti-tumoural | [66] |
miR-143-3p | LIMK1 expression LIMK1/CFL1 pathway |
Downregulated | Anti-tumoural | [67] |
miR-200b-3p/miR-429-5p | LIMK1 expression LIMK1/CFL1 pathway |
Downregulated | Anti-tumoural | [68] |
miR-139-5p | TGF-β, Wnt, MAPK, and PI3K | Downregulated | Anti-tumoural | [69] |
miR-212-5p | Prrx2 Wnt/β-catenin pathway |
Downregulated | Anti-tumoural | [70] |
miR-199a-5p | Downregulated | Anti-tumoural | [71] | |
miR-155 | Downregulated | Anti-tumoural | [72] | |
miR-34c-3p | MAP3K2 MAP3K2 pathway |
Downregulated | Anti-tumoural | [73] |
miR-3178 | Notch1 | Downregulated | Anti-tumoural | [74] |
miR-200b-3p | Downregulated | Anti-tumoural | [75] | |
miR-125b | MAP2K7 MAPK pathway |
Downregulated | Anti-tumoural | [76] |
miR-655 | Prrx1 | Downregulated | Anti-tumoural | [77] |
miR27-a | PTEN, PKB PI3K/AKT pathway |
Up-regulated | Pro-tumoural | [78] |
miR-182 | Inhibition of FOXF2 PFN1 |
Up-regulated Up-regulated |
Pro-tumoural Pro-tumoural |
[79] [80] |
miR-454 | PTEN PI3K/AKT pathway |
Up-regulated | Pro-tumoural | [81] |
miR-373 | HIF1α and TWIST HIF1α-TWIST pathway |
Up-regulated | Pro-tumoural | [82] |
miR-221/222 | ADIPOR1 and TRPS1 NF-κB, IL6, and JAK2/STAT3 pathway |
Up-regulated | Pro-tumoural | [83] |
miR-10b | TGF-β1-induced EMT pathway | Up-regulated | Pro-tumoural | [84] |